Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-Ep+-IgG-GFP
- Development stage
- Preclinical
- Lead developer
- Latus Bio
- Modality
- Gene Therapies
- Administration
- Intrathecal
01
Overview
AAV-Ep+-IgG-GFP is a gene therapy research construct consisting of an adeno-associated virus (AAV) vector with a novel AAV-Ep+ capsid that delivers a gene encoding an immunoglobulin G (IgG) antibody targeting Green Fluorescent Protein (GFP). It is primarily utilized as an isotype-control in preclinical studies investigating AAV-delivered antibody therapies for neurodegenerative diseases, such as C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The AAV-Ep+ capsid is specifically designed for high-efficiency transduction of neurons and ependymal cells in the brain and spinal cord, enabling the secretion of the encoded antibody into the cerebrospinal fluid (CSF). In experimental settings, this construct serves to establish a baseline for the effects of the viral delivery system and the expression of a non-therapeutic antibody, allowing for the rigorous evaluation of target-specific candidates like AAV-Ep+IgG1-GA.
- Other names
- AAV-Ep+ isotype-control
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)Low-density lipoprotein receptor (LDLR) family and Sialic acid
Beyond the preview
Go deeper on AAV-Ep+-IgG-GFP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AAV-Ep+-IgG-GFP.